Track ALT and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Altimmune Inc
910 Clopper Road, Gaithersburg, MD, United States, 20878
IPO
2005
Employees
57
Industry
Biotechnology
Sector
Healthcare
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20260+3
3
Q4 20250+3
3
2-quarter cumulative
0 sells6 buys
Analyst Ratings
4 analysts covering
Buy75%recommend buy
Buy
3
Hold
1
Sell
0